Recombinant Human NCR2/NKp44/CD336 Protein (His Tag)

A DNA sequence encoding the human NCR2 (NP_004819.2) extracellular domain (Met 1-Pro 190) was fused with a polyhistidine tag at the C-terminus.

Introducing the Recombinant Human NCR2/NKp44/CD336 Protein (His Tag), a cutting-edge product meticulously engineered to meet the highest standards of quality and performance. This protein, derived from human sources, has been carefully produced using advanced recombinant technology, ensuring its authenticity and purity.

The Recombinant Human NCR2/NKp44/CD336 Protein (His Tag) boasts a unique His Tag, which facilitates easy purification and detection, making it an invaluable tool for various research applications. Its exceptional stability and solubility further enhance its usability, allowing for seamless integration into a wide range of experimental protocols.

This protein exhibits remarkable biological activity, specifically targeting natural killer (NK) cells and acting as a crucial mediator in immune responses. Its interaction with ligands on target cells triggers a cascade of events, ultimately leading to the activation and cytotoxicity of NK cells. This pivotal role in immune regulation positions the Recombinant Human NCR2/NKp44/CD336 Protein (His Tag) as an indispensable asset in immunological studies and therapeutic developments.

Furthermore, the Recombinant Human NCR2/NKp44/CD336 Protein (His Tag) is meticulously manufactured under stringent quality control measures, ensuring batch-to-batch consistency and reliability. Its high purity and bioactivity are guaranteed, providing researchers with accurate and reproducible results.

In summary, the Recombinant Human NCR2/NKp44/CD336 Protein (His Tag) represents a breakthrough in the field of immunology, offering researchers a powerful tool to unravel the intricate mechanisms of NK cell activation and cytotoxicity. With its exceptional quality, stability, and biological activity, this protein is poised to revolutionize the landscape of immunological research and therapeutic advancements.